Advertisement
U.S. Markets closed

Alaunos Therapeutics, Inc. (TCRT)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Visitors trend2W10W9M
2.4130+0.2030 (+9.19%)
At close: 04:00PM EDT
2.3100 -0.10 (-4.27%)
After hours: 05:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.2100
Open2.3300
Bid1.9700 x 100
Ask2.7400 x 100
Day's Range2.3300 - 2.4300
52 Week Range2.0700 - 33.0000
Volume8,898
Avg. Volume24,790
Market Cap3.864M
Beta (5Y Monthly)-0.54
PE Ratio (TTM)N/A
EPS (TTM)-319.9700
Earnings DateNov 12, 2024 - Nov 18, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • TipRanks

    Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

    The latest announcement is out from Alaunos Therapeutics ( (TCRT) ). Alaunos Therapeutics, Inc. has decided to terminate its amended licensing agreement with Precigen, Inc. for developing neoantigen T-cell receptors to treat solid tumor cancers, signaling a shift in strategic priorities. The original agreement, in place since 2018, will end following Alaunos’s assessment of its business goals and the impending patent expiration of the Sleeping Beauty gene transfer platform in 2026. Despite this,

  • GlobeNewswire

    Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

    Best Response to TCR-T Best Response to TCR-T TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quar